Targeted Deletion of CD44v7 Exon Leads to Decreased Endothelial Cell Injury but Not Tumor Cell Killing Mediated by Interleukin-2-activated Cytolytic Lymphocytes*

Received for publication, April 29, 2003, and in revised form, July 14, 2003
Published, JBC Papers in Press, August 6, 2003, DOI 10.1074/jbc.M304467200

Robert J. McKallip, Michael Fisher‡, Yoonkyung Do‡, Andreas K. Szakal‡, Ursula Gunther‡, Prakash S. Nagarkatti‡§, and Mitzi Nagarkatti‡§**

From the Departments of ‡Microbiology and Immunology, ¶Pharmacology and Toxicology, and **Anatomy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia 23298 and the †Institute for Medical Microbiology, University of Basel, Petersplatz 10, CH-4030 Basel, Switzerland

The Journal of Biological Chemistry Vol. 278, No. 44, Issue of October 31, pp. 43818–43830, 2003

In the current study, we investigated the nature and role of CD44 variant isoforms involved in endothelial cell (EC) injury and tumor cell cytotoxicity mediated by IL-2-activated killer (LAK) cells. Treatment of CD44 wild-type lymphocytes with IL-2 led to increased gene expression of CD44v6 and v7 variant isoforms and to significant induction of vascular leak syndrome (VLS). CD44v6-v7 knockout (KO) and CD44v7 KO mice showed markedly reduced levels of IL-2-induced VLS. The decreased VLS in CD44v6-v7 KO and CD44v7 KO mice did not result from differential activation and expansion of CD8+ T cells, NK, and NK-T cells or from altered degree of perivascular lymphocytic infiltration in the lungs. LAK cells from CD44v7 KO mice showed a significant decrease in their ability to adhere to and mediate lysis of EC but not lysis of P815 tumor cells in vitro. CD44v7-mediated lysis of EC by LAK cells was dependent on the activity of phosphatidylinositols 3-kinase and tyrosine kinases. Interestingly, IL-2-activated LAK cells expressing CD44v7 but not CD44v6 were responsible for EC lysis. Furthermore, lysis of EC cells could be blocked by addition of soluble or enzymatic cleavage of CD44v6-v7-binding glycosaminoglycans. Finally, anti-CD44v7 mAbs caused a significant reduction in the adherence to and killing of EC and led to suppression of IL-2-induced VLS. Together, this study suggests that the expression of CD44v7 on LAK cells plays a specific role in EC injury and that it may be possible to reduce EC injury but not tumor cell killing by specifically targeting CD44v7.

Endothelial cell (EC) injury is a widely occurring pathological condition seen during a variety of infections, autoimmunity, transplantation, and graft-versus-host disease and follow-

* This work was supported in part by National Institutes of Health Grants RO1 AI 053703, RO1 DA 016545, P21 DA 014885, RO1 HL 058641, F32 HL 10455, F32 ES 01732, and RO1 ES 09098, as well as by American Cancer Society Grant IRG-100036. Flow cytometry was supported in part by National Institutes of Health Grant P30 CA 16059. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence and reprint requests should be addressed: Dept. of Microbiology and Immunology and Massey Cancer Center, Medical College of Virginia Campus, Virginia Commonwealth University, Box 980678, Richmond, VA 23298-0678. Tel.: 804-827-1555; Fax: 804-828-0676; E-mail: mnagark@hsc.vcu.edu.

The standard form of CD44, designated CD44s, is the most common form and has a size of 85–95 kDa (26). In addition to CD44s, a number of larger CD44 isoforms, ranging in size from 80 to 250 kDa, develop as a result of alternative splicing of variant exons (27). It has been suggested that expression of specific isoforms may play a role in the regulation of the immune response as well as in the development of autoimmune disorders. For example, CD44v7 has been shown to be involved
in the production of cytokines by B cells and to play a role in the interaction of T cells with antigen-presenting cells, and progenitor cells with stromal cells (17, 28). Other isoforms of CD44, such as CD44v6 and CD44v9, were shown to be involved in B cell adhesion to stromal cells (29). Treatment with anti-CD44v7 antibodies can inhibit the production of IL-2 and interferon-γ by CD8+ cells (28). In addition, studies have shown that trinitrobenzene sulfonate-induced colitis can be prevented and cured by treatment with anti-CD44v7 mAbs (30). Therefore, it is possible that specific CD44 variant isoforms play a role in mediating EC damage seen in disorders such as VLS.

In the current study, we examined whether specific CD44 isoforms play a role in mediating IL-2-induced VLS and tumor cytotoxicity. To this end, we screened splenocytes from mice treated with high doses of IL-2 for the expression of various CD44 isoforms and used CD44 variant knockout (KO) mice to examine whether the absence of specific isoforms would lead to reduced level of VLS. The results from this study demonstrated that CD44v7 plays an important role in the induction of vascular leak and EC damage following IL-2 treatment and that antibodies directed against CD44v7 can block IL-2-induced EC damage and VLS. Interestingly, CD44v7 did not play a role in the cytotoxicity of P815 tumor cells mediated by LAK cells. Together, the information in this study suggests that strategies designed to target the expression of CD44v7 may help to prevent EC damage seen in a variety of disorders.

**MATERIALS AND METHODS**

**Mice—**Adult female C57BL/6 (CD44 WT) mice were purchased from the National Institutes of Health (Bethesda, MD). CD44 KO mice represent those in which the entire CD44 gene is deleted; therefore, such mice fail to express all CD44 isoforms (10, 31). CD44v7 KO and CD44v6-v7 mice are those with targeted deletion of CD44v7 or CD44v6 and v7 exon products, respectively. Such mice, therefore, fail to express CD44 isoforms bearing the variant exon v7 or v6 and v7, respectively (30). All these strains were on C57BL/6 background. The CD44 KO, CD44v6-v7 KO, and CD44v7 KO mice were bred in the animal facilities at the Medical College of Virginia Campus, Virginia Commonwealth University, and screened for the CD44, CD44v6-v7, and CD44v7 deletion, respectively. TIE2-GFP mice were purchased from the Jackson Laboratory (Bar Harbor, ME). These mice express green fluorescent protein (GFP) under the control of the endothelial-specific receptor tyrosine kinase (TIE2) promoter (32).

**Cell Lines—**TME (an endothelial cell line; H-2b), SVCH (a fibroblast cell line; H-2b), and P815 (a mastocytoma) were maintained in RPMI 1640 containing 10% FCS as described (33).

**RNA Isolation and RT-PCR Analysis—**Total RNA was isolated from single cell suspension of splenocytes using the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA concentration was determined spectrophotometrically, and the integrity of the each preparation was verified by agarose gel electrophoresis. CDNA was synthesized by reverse transcription of 50 ng of total RNA using the SensiScript RT Kit (Qiagen). All PCR reactions were prepared using MasterAmp PCR Premix F (Epicerent Technologies, Madison, WI) according to the recommendations from the manufacturer, and using Platinum TaqDNA polymerase (Invitrogen, Carlsbad, CA). A half-nested RT-PCR approach was used to amplify CD44 isoforms, as endogenous isoform expression is too low to be detected directly by RT-PCR (data not shown). An initial amplification using primers CD44 U and CD44 L, homologous to the standard form and all isoforms. The products of this reaction were used as template in a second reaction using a CD44 isoform-specific primer pair to amplify specific CD44 isoforms (CD44 L and CD44 isoform U). The primers used are described in Table I.

**Cloning and DNA Sequencing—**PCR products were cloned using the TOPO TA Cloning Kit (Invitrogen). After overnight incubation at 37°C on LB plates containing ampicillin (100 μg/ml) and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), positive (white) colonies were subcultured in 300 μl of LB medium at 37°C for 4 h. Two μl of each culture was used as template in a PCR reaction to confirm the presence of an insert. Cultures containing CD44 isoform products were grown overnight in 3 ml of LB medium. Plasmids were isolated using the Spin Miniprep Kit (Qiagen). Plasmids were sequenced using the M13 Reverse and M13 Forward (-40) primers, and using ABI BigDye terminator (version 2) chemistry (Applied Biosystems, Foster City, CA).

**Antibodies—**PE- or FITC-conjugated anti-CD3, anti-CD4, anti-CD8, anti-CD16 (Fc block), anti-CD19, anti-CD25, anti-CD44, Mac-3, and anti-NK1.1 mAbs were purchased from Pharmingen (San Diego, CA). Anti-CD44v7 mAbs (LN7.1) were prepared as previously described (34). Briefly, CD44v6-v7 KO mice were immunized with 100–200 μg of CD44v6-v10/glutathione S-transferase (GST) fusion protein, three times over a 12-day period. Two days following the last immunization, the cells from the regional lymph nodes were fused using the X63-Ag8.2 myeloma cell line. The epitope recognized by LN7.1 was mapped and was shown to recognize the following peptide located within the CD44v7 region: QEDSVSTDFDDPIHP (30). The mAbs were purified from cell culture supernatants using protein G-Sepharose columns (Amersham Biosciences), and isotypes of the mAbs were determined using commercially available kits (Serotec, Roche Molecular Biochemicals) (30). Isotype control mAbs (mouse IgG1) were purchased from Pharmingen.

**Flow Cytometric Analysis of Cell Surface Markers and Cell Sorting—**Splenocytes from mice treated with high dose IL-2, as described below, or splenocytes stimulated with IL-2 in vitro were analyzed for the expression of various cell surface markers. Nonspecific staining was
blocked by incubation of the cells with Fc block (PharMingen) for 15 min. The expression of various cell surface markers were determined by staining the cells with FITC- or PE-conjugated mAbs for 30 min on ice, followed by washing three times. The cells were analyzed by flow cytometry. In experiments in which CD44 cell expressing low (CD44<sup>lo</sup>) and high (CD44<sup>hi</sup>) levels of CD44 were separated, nonstaining cells were blocked by incubation of the cells with Fc block (PharMingen) for 15 min. Next, the cells were stained with PE-conjugated anti-CD44 mAbs (IM7) for 30 min on ice and washed twice with PBS. The CD44<sup>lo</sup> and CD44<sup>hi</sup> cells were separated using an Epics 753 cell sorter (Beckman Coulter, Fullerton, CA).

Quantification of Vascular Leak Syndrome—Vascular leak was studied by measuring the extravasation of Evan's blue, which, when given intravenously to plasma protein, particularly albumin, extravasation following extravasation can be detected in various organs as described previously (10, 35, 36). Vascular leak was induced by injection of IL-2 as previously described (9, 10). Each mouse was individually analyzed for vascular leak, and data from five mice were expressed as mean ± S.E. percentage increase in VLS in IL-2 treated mice when compared with that seen in PBS-treated controls (9, 10).

Histological Analysis—Groups of three mice were injected with IL-2 or PBS as described above, and on day 4, the mice were studied for VLS induction. The VLS seen in IL-2-treated mice was expressed as percentage of increase in extravasation when compared with that of PBS-treated controls and was calculated as: (optical density of dye in the lungs of IL-2-treated mice) − (optical density of dye in the lungs of PBS-treated controls)/optical density of dye in the lungs of PBS-treated mice × 100. Each mouse was studied for vascular leak, and data from five mice were mean as ± S.E. percentage increase in VLS in IL-2 treated mice when compared with that seen in PBS-treated controls (9, 10).

Generation of LAK Cells—Spleens were harvested from CD44 WT or CD44v7 KO mice (10). Next, the recipient mice received IL-2 treatment (75,000 units, three times a day for 3 days) or PBS as described above, and on day 4, the mice were studied for VLS induction. The VLS seen in IL-2 treated mice was expressed as percentage of increase in extravasation compared with that of PBS-treated controls and was calculated as: (optical density of dye in the lungs of IL-2 treated mice) − (optical density of dye in the lungs of PBS-treated controls)/optical density of dye in the lungs of PBS-treated mice × 100. Each mouse was studied for vascular leak, and data from five mice were mean as ± S.E. percentage increase in VLS in IL-2 treated mice when compared with that seen in PBS-treated controls (9, 10).

Histological Analysis—Groups of three mice were injected with IL-2 or PBS as described earlier, and on day 4, the lungs were fixed in 10% formalin solution. The organs were embedded in paraffin, sectioned, and stained with hematoxylin and eosin, as described (9, 10). Perivascular infiltration was scored by counting the number of lymphocytes infiltrating the vessel and averaging the minimum and maximum range for each group. Four samples per mouse were analyzed, and a minimum of four mice were included.

Cell Aggregation—Cell aggregation was visualized using a protocol as described by Matsumoto et al. (25). In experiments using TME EC, LAK cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, OR) and EC were labeled with PKH26-GL fluorescent cell linker compound (PKH, Sigma-Aldrich). In experiments using GFP-positive EC isolated from TIE2-GFP mice, LAK cell and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL. In experiments using EC isolated from TIE2-GFP mice, LAK cell were labeled with PKH26-GL and EC were labeled with PKH26-GL.
TIE2-GFP mice, mechanically dissected, and digested in collagenase (0.5 mg/ml) for 1 h at 37 °C. The cells were washed twice in PBS containing 2.5% FCS and incubated with murine serum to block Fc receptors. The cells were cultured with rat anti-mouse CD31 and CD105 mAbs as well as biotinylated isoelectin B4 for 30 min on ice. Next, the cells were washed and cultured with goat anti-rat IgG-conjugated microbeads and streptavidin-conjugated microbeads for 15 min on ice. The cells were then passed through a MACS separation unit, and the cells magnetically retained were eluted. The purity of EC was confirmed by analyzing the cells for GFP using a flow cytometer, and the EC preparation was found to be >95% GFP-positive.

**Statistical Analysis**—Analysis of variation and Student’s t test were used to determine statistical significance, and p < 0.05 was considered to be statistically significant.

**RESULTS**

**Up-regulation of CD44v7 and CD44v6-v7 Variant Isoforms after IL-2 Treatment in Vivo**—To determine whether IL-2 treatment led to the differential regulation of CD44 variant isoform expression, spleen cells from CD44 WT mice injected with IL-2 or PBS, as described under “Materials and Methods,” were harvested on day 4 and analyzed for the expression of various CD44 isoforms. The results showed that treatment with IL-2 in vivo led to the expression of a number of CD44 variant isoforms (Fig. 1). Most notable was the dramatic induction of isoforms containing alternatively spliced exons v6 and v7 (compare PBS versus IL-2; see Fig. 1, panels 1, 2, 4, and 5). Amplification using a v7 reverse primer and CD44 conserved region forward primer (Fig. 1, panel 1) did not yield a product in PBS-treated sample. However, in IL-2-treated samples, products of 191 and 317 bp were generated. Cloning and sequence analysis of these products revealed them to be isoforms containing v7 alone and v6-v7, respectively. Similarly, amplification using a v7 forward primer and CD44 conserved region reverse primer also yielded no product in the PBS-treated sample. Cloning and sequence analysis revealed that the faint band seen in the PBS lane (Fig. 1, panel 2) is a nonspecific artifact, resulting from the half-nested amplification strategy used. Two products of 288 and 459 bp were generated in the IL-2-treated samples, which, following cloning and sequencing, were revealed to contain v7 alone and v7-v8, respectively. CD44v6 isoforms were amplified using a v6 reverse primer and CD44 conserved region forward primer (Fig. 1, panel 5). A 328-bp product was amplified in the PBS-treated sample, which was found to contain exons v6 and v5. Amplification of the IL-2-treated sample resulted in products of 211, 328, and 410 bp. Sequencing of the 211- and 328-bp products revealed them to be v6 alone and v6-v5, respectively. The expression of v6 and v5 was confirmed by amplification using a v5-specific forward primer and CD44 conserved region reverse primer (Fig. 1, panel 4). No products were amplified in the PBS-treated sample; however, bands of 310 and 436 bp were amplified from IL-2-treated samples. Sequencing of these products confirmed them to be v5 alone and v5-v6. In addition, IL-2 treatment resulted in up-regulation of isoforms containing v8 and v8-v9 (Fig. 1, panel 3). Isoforms containing v3 were found to be constitutively expressed, and were not affected by IL-2 treatment (Fig. 1, panels 6 and 7).

**Decreased VLS in CD44v7 KO and CD44v6-v7 KO Mice**—To investigate the role of CD44v7 and CD44v6 isoforms in IL-2-induced VLS, CD44 WT, CD44 KO, CD44v7 KO, and CD44v6-v7 KO mice were injected with 75,000 units of IL-2 three times daily for 3 days and once on day 4. On the last day, the mice were injected with 1% Evan’s blue and VLS was studied by determining the extravasation of the dye in the lungs. Fig. 2 shows a representative experiment in which the CD44 WT mice displayed significant VLS following IL-2 treatment and CD44 KO mice showed marked decrease in VLS as reported previously (10). Interestingly, the CD44v7 KO and CD44v6-v7 KO mice also exhibited significantly lower levels of VLS in the lungs. The decreased VLS seen in CD44v7 KO mice was similar to that observed in CD44 KO and CD44v6-v7 KO mice, suggesting that the product of the v7 exon may play a specific role in the induction of IL-2-induced VLS. Inasmuch as, in an earlier study we had extensively investigated the IL-2-induced VLS in CD44 KO mice (10), all subsequent experiments were confined to CD44v7 KO and CD44v6-v7 KO mice.

**Histological Analysis of Lungs from IL-2-treated Mice**—Previous studies demonstrated that IL-2 treatment triggered marked infiltration of lymphocytes and macrophages in the lungs (9, 10). Histological studies were therefore conducted to determine whether the reduced levels of VLS seen in CD44v7 KO and CD44v6-v7 KO mice were caused by an alteration in the migration of mononuclear cells into the lungs. Mice were injected with PBS or IL-2, as described in Fig. 2. On day 4, the...
lungs were harvested and stained with hematoxylin and eosin (Fig. 3, A–D). The lungs from the PBS-treated mice did not show any perivascular infiltration. In contrast, the IL-2-treated CD44 WT mice exhibited significant perivascular infiltration consisting mainly of lymphocytes around the pulmonary vein. In comparison, the lungs from CD44v7 KO and CD44v6-v7 KO mice treated with IL-2 showed similar levels of perivascular infiltration as the IL-2-treated CD44 WT mice (Fig. 3E). These data suggested that the decrease in IL-2-induced VLS seen in CD44v7 KO and CD44v6-v7 KO mice was not the result of alterations in the ability of mononuclear cells to infiltrate into the lungs.

The Effect of IL-2 Treatment in Vivo on the Expansion of Effector Cell Populations in CD44 WT, CD44v6-v7 KO, and CD44v7 KO Mice—We examined whether the reduction in the level of VLS seen in CD44v7 KO and CD44v6-v7 KO mice when compared with CD44 WT mice resulted from altered expansion of the effector cells. To this end, CD44 WT, CD44v7 KO, and CD44v6-v7 KO mice were treated with IL-2, as described above. After the final injection of IL-2 on day 4, spleens were harvested, cellularity was determined and the cells were stained for the expression of CD4, CD8, and combined CD3 and NK1.1. IL-2 treatment caused marked and somewhat similar increase in the percentage and total number of CD8 T cells, NK cells, and NK-T cells (Table II). Similar results were seen in the CD44v7 KO and CD44v6-v7 KO mice, indicating that the reduction in VLS seen in these mice was not the result of an alteration in the expansion of CD8+ cells in vivo. The effect of IL-2 treatment on NK (CD3 NK1.1+) and NK-T (CD3 NK1.1+ cells) was investigated, it was observed that IL-2 caused a similar increase in the percentage and total number (Fig. 4, Table II) of NK and NK-T cells in CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice. Together these results suggested that treatment with IL-2 led to the expansion of CD8+ T cells, NK cells, and NK-T cells and that this expansion was not altered in CD44v7 KO or CD44v6-v7 KO mice when compared with CD44 WT mice.

IL-2-activated Killer Cell Activity against Endothelial Cell (EC) Targets Is Reduced in CD44v6-v7 and CD44v7 KO Mice in Vitro and in Vivo—IL-2-activated cytotoxic cells can kill EC and induce VLS (33). Therefore, we compared the ability of splenocytes from IL-2-treated CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice to lyse TME, a well characterized endothelial cell line. To this end, CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice were treated with IL-2 for 4 days, as described above. The splenocytes were harvested and tested for cytotoxicity against EC targets using a standard chromium release assay (Fig. 5A). The results demonstrated that splenocytes from CD44 WT mice caused significant lysis of EC. However, the lysis of the EC was greatly diminished in the cultures containing the CD44v6-v7 and CD44v7 KO splenocytes.

The decreased LAK activity of splenocytes from CD44 WT mice against EC was further confirmed by experiments in which splenocytes from CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice were cultured with high concentrations of IL-2 (1000 units/ml) for 48 h in vitro and examined for their ability to lyse TME, SVC3H fibroblasts, and P815 tumor cells. The results showed that IL-2-activated cytotoxic cells from CD44v6-v7 KO and CD44v7 KO mice exhibited decreased ability to kill EC when compared with the LAK cells from the CD44 WT mice (Fig. 5B). The lytic activity was spe-

**Fig. 2.** VLS induction following IL-2 treatment in vivo. CD44 WT, CD44 KO, CD44v7 KO, and CD44v6-v7 KO mice were injected intraperitoneally with 75,000 units of IL-2 alone 3 times daily for 3 days and once on day 4 or with PBS. Two hours after the last injection with IL-2, the mice were injected with 1% Evans blue, and VLS was studied by determining the extravasation of Evans blue dye in the lungs. The vertical bars represent the percentage of increase in VLS ± S.E. following IL-2 treatment compared with that in the PBS-treated controls as described in "Materials and Methods." Asterisks indicate statistically significant difference when compared with the CD44 WT controls, *p < 0.05.

**Fig. 3.** Histological studies of lungs following IL-2 administration. Lungs from CD44 WT mice treated with PBS (A) and lungs from CD44 WT (B), CD44v6-v7 KO (C), and CD44v7 KO (D) mice treated with IL-2 were harvested, preserved in 10% formalin solution, sectioned, and stained with hematoxylin and eosin. Arrows indicate perivascular infiltration, consisting mostly of lymphocytes. E. The level of perivascular infiltration was determined by counting the number of cells infiltrating a venule. The data depict the mean ± S.E. of sections from four individual mice.
specific for endothelial cells, as the LAK cells were unable to cause significant lysis of SVC3H fibroblasts bearing the same MHC molecules as the TME EC (Fig. 5C). Interestingly, the ability of the LAK cells from CD44v6-v7 KO and CD44v7 KO mice to lyse the P815 tumor targets was not significantly affected when compared with LAK cells from CD44 WT mice (Fig. 5D). Together, these results suggested that the reduction in IL-2-induced VLS in CD44v6-v7 KO and CD44v7 KO mice may be the result of reduced EC killing.

Recently, it was shown that CD44-dependent cytolysis could be distinguished from natural cytotoxicity according to the sensitivity to inhibition by the PI 3-kinase inhibitor, wortmannin (24). More specifically, it was shown that CD44-dependent cytolysis was highly sensitive to wortmannin inhibition, whereas natural cytotoxicity was relatively resistant. Therefore, we examined the effect of wortmannin (5 nM) treatment on the ability of LAK cells to mediate lysis of EC as well as P815 tumor cells. The results demonstrated that the lysis of EC was significantly inhibited by wortmannin, whereas the lysis of P815 was generally unaffected (Fig. 5E). In addition, we examined the effect of the tyrosine kinase inhibitor, herbimycin (0.52 μM), on LAK-mediated lysis of EC and P815. Exposure of LAK cells to herbimycin effectively inhibited their ability to lyse EC but not P815 tumor cells (Fig. 5E). Together, these results suggest that both PI 3-kinase and tyrosine kinases play an important role in LAK cell lysis of EC and that the mechanism

### Table II

| Cellularity*  | Splenocyte populations* |
|---------------|-------------------------|
|               | CD4*  | CD8*  | CD3-NK.1* | CD3-NK.1* |
| cell no. × 10⁶/spleen |       |       |           |           |
| CD44 WT + PBS    | 131.8 ± 8.2 | 24.7 (32.6) | 14.8 (19.5) | 8.5 (11.2) | 1.3 (1.7) |
| CD44 WT + IL-2    | 194.9 ± 2.3 | 28.6 (26.2) | 11.2 (11.1) | 8.5 (8.4)  | 0.7 (0.7)  |
| CD44v7 KO + IL-2  | 192.2 ± 10.4 | 15.9 (30.5) | 21.4 (41.1) | 24.21 (46.5) | 2.8 (5.4) |
| CD44v6-v7 KO + PBS | 85.1 ± 5.3 | 24.7 (21.0) | 15.0 (12.8) | 13.35 (9.7) | 1.2 (1.0)  |
| CD44v6-v7 KO + IL-2 | 198.5 ± 3.2 | 15.5 (30.6) | 21.2 (42.1) | 26.6 (52.6) | 4.2 (8.3)  |

* Mice were treated with IL-2 (75,000 units/mouse three times daily for 4 days) or the vehicle. On day 4, the spleens were harvested and the total cellularity was determined.

* Splenocyte subsets were determined using flow cytometry. The data represent the percentage of CD4+ T cells, CD8+ T cells, CD3+ NK.1+ cells, and CD3+ NK.1+ cells in the spleens obtained from 3 mice. The numbers in parentheses represent the mean total cellularity × 10⁶ of each cell population found in the spleens.

* Data represent mean ± S.E. obtained from 3 mice.
We examined whether the cytolytic activity of IL-2-activated splenocytes express high or low levels of CD44 was mediated by CD44lo and/or CD44hi cells, and, if so, whether the cytotoxicity exhibited by these subpopulations was altered in CD44v7 KO mice. To this end, splenocytes CD44 WT or CD44v7 KO mice were stimulated with IL-2 (1000 units/ml) for 48 h with IL-2 (1000 units/ml) and stained with PE-conjugated anti-CD44 mAbs and sorted according to the level of CD44 expression. The cells were then stained with PE-conjugated anti-CD44 mAbs (IM7) and then sorted by FACS into CD44 WT and CD44v7 KO mice. The importance of LAK cell expression of CD44v7 was confirmed in a crisscross mixing experiment. To this end, splenocytes from CD44 WT or CD44v7 KO mice were stimulated with IL-2 for 48 h. The LAK cells were then stained with CFSE and then cultured with freshly isolated lung EC from either CD44 WT or CD44v7 KO mice. The lytic activity was determined following 4 h of culture by staining the cells with propidium iodide. Cells staining negative for CFSE were gated, and the percentage of cells positive for propidium iodide was calculated (Fig. 7A). The results demonstrated that the percentage of EC lysed by LAK cells from CD44 WT mice was significantly greater than the percentage of EC targets lysed by LAK cells from CD44v7 KO mice, regardless of the expression of CD44v7 on the EC targets. Together, these results suggested that the expression of CD44v7 on IL-2-activated LAK cells plays an important role in mediated EC lysis.

**Expression of CD44v7 on LAK Cells Plays an Important Role in IL-2-induced EC Damage and VLS**—To further corroborate in vivo that CD44v7 expression on LAK cells plays a critical role in VLS, we performed experiments in which splenocytes from CD44 WT and CD44v7 KO mice were adoptively transferred into CD44 WT or CD44v7 KO recipient mice followed by IL-2 treatment (Fig. 7A). The results demonstrated that transfer of CD44 WT splenocytes into CD44 WT or CD44v7 KO mice led to a significant increase in IL-2-induced VLS when compared with the transfer of splenocytes from CD44 WT or CD44v7 KO mice into CD44 WT or CD44v7 KO mice. The importance of LAK cell expression of CD44v7 was confirmed in a crisscross mixing experiment. To this end, splenocytes from CD44 WT or CD44v7 KO mice were stimulated with IL-2 for 48 h. The LAK cells were then stained with CFSE and then cultured with freshly isolated lung EC from either CD44 WT or CD44v7 KO mice. The lytic activity was determined following 4 h of culture by staining the cells with propidium iodide. Cells staining negative for CFSE were gated, and the percentage of cells positive for propidium iodide was calculated (Fig. 7A). The results demonstrated that the percentage of EC lysed by LAK cells from CD44 WT mice was significantly greater than the percentage of EC targets lysed by LAK cells from CD44v7 KO mice, regardless of the expression of CD44v7 on the EC targets. Together, these results suggested that the expression of CD44v7 on IL-2-activated LAK cells plays an important role in mediated EC lysis.

**The Reduced Lytic Activity of LAK Cells from CD44v6-v7 KO and CD44v7 KO Mice Is Not the Result of Alterations in Activation or Expression of Cytolytic Effector Molecules**—We examined the possibility that the reduced IL-2-induced EC damage seen in CD44v6-v7 KO and CD44v7 KO mice resulted from decreased responsiveness to activation stimuli and/or because of a reduction in the expression of effector molecules involved in the lytic activity of LAK cells. To this end, splenocytes were cultured in the presence of IL-2 (Fig. 8A) or ConA (Fig. 8B) for 48 h and the proliferative responsiveness was measured. The results showed that splenocytes from the CD44v6-v7 KO and CD44v7 KO mice responded to IL-2 or ConA to the same extent as cells from CD44 WT mice. Similar results were seen when the levels of CD69, an activation marker, were measured using FACS analysis (Fig. 8C). These results suggested that the reduced induction of VLS seen in the CD44v6-v7 KO and CD44v7 KO mice was not the result of a defect in the activation and proliferation of T cells from these mice.

Increased levels of FasL, perforin, and TNF-α play an important role in the cytolytic activity of lymphocytes. Therefore, we examined the expression of FasL, perforin and TNF-α mRNA in splenocytes following injection of PBS (control) or IL-2 in vivo (Fig. 8D). Splenocytes from IL-2-treated CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice were found to express increased levels of FasL when compared with PBS-treated mice. Such an increase was similar in all three groups of mice. IL-2 treatment caused a modest or no significant increase in...
the levels of perforin and TNF-α mRNA in all three groups of mice when compared with their PBS-treated counterparts. Moreover, the levels of mRNA for perforin and TNF-α were similar in these three groups of mice treated with PBS or IL-2. These results suggested that the reduced IL-2-induced VLS and decreased lytic activity against EC seen in the CD44v6-v7 KO and CD44v7 KO mice did not result from reduced expression of cytolytic effector molecules.

Previous studies from our laboratory have shown that IL-2 treatment in vitro leads to increased expression of CD44 (9, 10). Because the CD44v6-v7 and CD44v7 isoforms have been specifically deleted from the CD44v6-v7 KO and CD44v7 KO mice, respectively, IL-2 stimulation should still lead to up-regulation of remaining CD44 isoforms in these mice. Therefore, we examined whether the expression of CD44 was increased in CD44v6-v7 KO and CD44v7 KO mice following IL-2 treatment. CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice were treated for 4 days with IL-2 as described above. After which, the splenocytes were analyzed for the expression of CD44 using a pan antibody, IM7, which recognizes all isoforms of CD44 (Fig. 8E). The results showed that there was a significant increase in the expression of CD44 in splenocytes from CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice following IL-2 treatment in vitro, which was similar in all three groups of mice.

It is possible that the increased expression of CD44 on splenocytes seen after IL-2 treatment in vitro may result from migration of CD44 cells into the spleen rather than direct activation of LAK cells. To address this, the effect of in vitro IL-2 stimulation of splenocytes on the expression of CD44 isoforms containing the CD44v6 and CD44v7 exons was determined. To this end, splenocytes from CD44 WT and CD44v7 KO mice were stimulated for 48 h with 1000 units/ml IL-2. As shown in Fig. 8F, stimulation with IL-2 in vitro caused an increase in the expression of CD44 isoforms containing the v6 and v7 exons in splenocytes from CD44 WT mice. In comparison, CD44 isoforms containing the v6 exon but not the v7 exon were increased in splenocytes from CD44v7 KO mice. It should be noted that the PBS-injected control mice failed to exhibit CD44v6-v7 when directly tested (Fig. 1A), whereas the in vitro control cultures of splenocytes incubated with medium alone showed CD44v6-v7 expression. This can be explained by the fact that in vitro culture conditions provide fetal calf serum and other growth factors, which may activate some splenocytes to express CD44v6-v7. Fig. 8G depicts the level of CD44 protein expression of splenocytes from CD44 WT or CD44v7 KO mice following 48-h culture of splenocytes with or without IL-2 in vitro. CD44 expression was determined by staining splenocytes with anti-CD44 mAbs (IM7), which recognizes both the standard form and all isoforms of CD44, followed by flow cytometric analysis. The results showed that, following stimulation with IL-2 in vitro, CD44 expression increased to a similar extent in splenocytes from CD44 WT and CD44v7 KO mice, as indicated by an increase in the mean fluorescence intensity.

Adherence and Cell Aggregation Between EC and IL-2-induced LAK Cells from CD44 WT and CD44v7 KO Mice in Vitro—We next examined the possibility that the absence of CD44v7 on IL-2-activated lymphocytes leads to a reduction in their adherence to EC. To quantify the adhesion, LAK cells from CD44 WT and CD44v7 KO mice were labeled with [3H]thymidine and cultured with confluent layers of EC for 2 h. The percentage of cells adhering to the EC was determined as described under "Materials and Methods." The results showed that there was significant adhesion between EC and IL-2-activated splenocytes from the CD44 WT mice (Fig. 9A). In contrast, the IL-2-activated splenocytes from the CD44v7 KO mice showed a reduced capacity to adhere to the EC. The effect on adherence of LAK cells to EC was further demonstrated using PKH-labeled LAK cells and CFSE-labeled EC (Fig. 9C). In this experiment, increased numbers of LAK cells from CD44 WT mice bound to the EC when compared with the CD44v7 KO mice.

Because TME is an established cell line and inasmuch as EC from the lungs may be unique, we examined whether IL-2-activated splenocytes from CD44v7 KO mice had a reduced capacity to form conjugates with freshly isolated primary lung EC. To this end, we isolated EC from TIE2-GFP transgenic mice in vitro. We next examined the possibility that the absence of CD44v7 on IL-2-activated lymphocytes leads to a reduction in their adherence to EC. To quantify the adhesion, LAK cells from CD44 WT and CD44v7 KO mice were labeled with [3H]thymidine and cultured with confluent layers of EC for 2 h. The percentage of cells adhering to the EC was determined as described under “Materials and Methods.” The results showed that there was significant adhesion between EC and IL-2-activated splenocytes from the CD44 WT mice (Fig. 9A). In contrast, the IL-2-activated splenocytes from the CD44v7 KO mice showed a reduced capacity to adhere to the EC. The effect on adherence of LAK cells to EC was further demonstrated using PKH-labeled LAK cells and CFSE-labeled EC (Fig. 9C). In this experiment, increased numbers of LAK cells from CD44 WT mice bound to the EC when compared with the CD44v7 KO mice.
The Role of CD44v7 in LAK-mediated Endothelial Cell Damage

To this end, mice were injected for 4 days with IL-2. In parallel studies, anti-CD44v7 mAbs had no effect on the killing of P815 tumor cells. Finally, we examined the effect of anti-CD44v7 mAbs on the lysis of EC by LAK cells. To this end, LAK cells were cultured with anti-CD44v7 mAbs in plates containing TME endothelial cells. LAK cells not adhering to TME cells were removed by gently washing with medium. Adherent cells were quantified by measuring the [3H]thymidine activity and compared with the [3H]thymidine activity of cells removed from wells without TME cells (total activity). The percentage of LAK cells adhering to the TME was determined as described under “Materials and Methods.”

Results showed that anti-CD44v7 mAbs effectively blocked the adherence of LAK cells to EC. To this end, [3H]thymidine-labeled LAK cells and soluble anti-CD44v7 mAbs or [3H]thymidine-labeled LAK cells and soluble isotype control antibodies were added to plates coated with EC (Fig. 10A). The percentage of LAK cells adhering to the EC was determined 2 h later as described under “Materials and Methods.” The results showed that anti-CD44v7 mAbs significantly reduced the percentage of endothelial cells from TIE2-GFP mice conjugated to at least one LAK cell per field. The data depicted represent the mean ± S.E. from 10 randomly chosen fields. Asterisk indicates statistically significant difference when compared with the CD44 WT mice, p < 0.05. D, cell aggregation was visualized by centrifuging PKH-labeled LAK cells (yellow) with endothelial cell (green) isolated from TIE2-GFP mice as described under “Materials and Methods.” Cell aggregation was visualized using a fluorescent microscope (original magnification, ×400).

Fig. 9. Adherence and cell aggregation between endothelial cells and IL-2-induced LAK cells from CD44 WT and CD44v7 KO mice in vitro. A, [3H]thymidine-labeled LAK cells were cultured for 2 h in plates containing TME endothelial cells. LAK cells not adhering to TME cells were removed by gently washing with medium. Adherent cells were quantified by measuring the [3H]thymidine activity and compared with the [3H]thymidine activity of cells removed from wells without TME cells (total activity). The percentage of LAK cells adhering to the TME was determined as described under “Materials and Methods.” Asterisk indicates statistically significant difference when compared with the CD44 WT splenocytes, p < 0.05. C, in parallel studies, PKH-labeled LAK cells (red) were cultured with CFSE-labeled TME cells (green). Cell aggregation was visualized using a fluorescent microscope (original magnification, ×400). B, cell aggregation between LAK cells and freshly isolated endothelial cells was quantified by counting the percentage of endothelial cells from TIE2-GFP mice conjugated to at least one LAK cell per field. The data depicted represent the mean ± S.E. from 10 randomly chosen fields. Asterisk indicates statistically significant difference when compared with the CD44 WT mice, p < 0.05. D, cell aggregation was visualized by centrifuging PKH-labeled LAK cells (yellow) with endothelial cell (green) isolated from TIE2-GFP mice as described under “Materials and Methods.” Cell aggregation was visualized using a fluorescent microscope (original magnification, ×400).

adhering to TIE2-GFP lung EC are shown in Fig. 9D. These results further confirmed that the level of cell aggregation between LAK cells and freshly isolated lung EC was significantly greater in CD44 WT mice when compared with CD44v7 KO mice.

Fig. 8. Reduced lytic activity of LAK cells from CD44v6-v7 KO and CD44v7 KO mice is not the result of alteration in proliferation/activation or expression of effector molecules such as Fas ligand, perforin, or TNF-α. Splenocytes from CD44 WT and CD44v7 KO mice were stimulated for 48 h with interleukin-2 (1000 units/ml) (A) or ConA (5 μg/ml) (B). During the final 8 h of culture, the cells were pulsed with 2 μCi of [3H]thymidine. Thymidine incorporation was determined by β-scintillation counting. The data represent mean ± S.E. of triplicate wells. C, activation was further assessed by examining the effect of ConA and IL-2 on CD69 expression by FACS analysis. D, detection of Fas ligand, perforin, and TNF-α mRNA in splenocytes from PBS- or IL-2-treated mice. Total RNA was isolated from splenocytes of PBS- or IL-2-injected mice as described in Fig. 1. mRNA was reverse transcribed and amplified by PCR with primers specific for Fas ligand, perforin, TNF-α, and β-actin. Lane 1, CD44 WT + PBS; lane 2, CD44 WT + IL-2; lane 3, CD44v6-v7 KO + PBS; lane 4, CD44v6-v7 + IL-2; lane 5, CD44v7 KO + PBS; lane 6, CD44v7 KO + IL-2. A photograph of ethidium bromide-stained amplicons is depicted. E, the expression of CD44 on splenocytes from CD44 WT, CD44 KO, CD44v6-v7 KO, and CD44v7 KO mice following activation with IL-2 in vivo was determined using FACS analysis. F, the expression of CD44 isoform mRNA containing the v6 or v7 exon in splenocytes unstimulated or stimulated with IL-2 (1000 units/ml) for 48 h was determined by RT-PCR analysis. G, the expression of CD44 on splenocytes from CD44 WT and CD44v7 KO mice following activation with IL-2 in vitro was determined using FACS analysis.

The Effect of Anti-CD44v7 mAbs on LAK Cell Adherence to and Lysis of EC in Vitro and IL-2-induced VLS in Vivo—To further confirm the involvement of CD44v7 in IL-2-induced EC damage and VLS, we examined the effect of anti-CD44v7 mAbs on LAK cell adherence to and killing of EC. First, we examined the effect of anti-CD44v7 mAbs on the ability of LAK cells to adhere to EC. To this end, [3H]thymidine-labeled LAK cells and soluble anti-CD44v7 mAbs or [3H]thymidine-labeled LAK cells and soluble isotype control antibodies were added to plates coated with EC (Fig. 10A). The percentage of LAK cells adhering to the EC was determined 2 h later as described under “Materials and Methods.” The results showed that anti-CD44v7 mAbs effectively blocked the adherence of LAK cells to EC. Next, we examined the effect of anti-CD44v7 mAbs on the lysis of EC by LAK cells. To this end, LAK cells were cultured with anti-CD44v7 or isotype control mAbs with 51Cr-labeled EC or P815 tumor cells and cytotoxicity was studied using the 4-h chromium release assay. The results showed that incubation with anti-CD44v7 mAbs significantly reduced LAK cell lysis of EC (Fig. 10B). Interestingly, incubation with anti-CD44v7 mAbs had no effect on the killing of P815 tumor cells. Finally, we examined whether treatment with anti-CD44v7 mAbs would have any effect on the level of IL-2-induced VLS (Fig. 10C). To this end, mice were injected for 4 days with IL-2. In addition, the mice were treated daily with isotype control mAbs.
The Role of CD44v7 in LAK-mediated Endothelial Cell Damage

Fig. 10. Anti-CD44v7 mAbs inhibit LAK cell adherence to and lysis of endothelial cells in vitro as well as the induction of IL-2-induced VLS in vitro. A, the effect of anti-CD44v7 mAbs on the adherence of LAK cells to TME endothelial cells was determined by culturing [3H]thymidine-labeled LAK cells + anti-CD44v7 mAbs or isotype control mAbs on plates coated with TME cells. The percentage of LAK cells adhering to the TME cells was determined 2 h later as described under “Materials and Methods.” B, to examine the effect of anti-CD44v7 mAbs on the lysis of TME cells, LAK cells were cultured with anti-CD44v7 mAbs (10 μg/ml) or isotype control mAbs (10 μg/ml) and directed against 51Cr-labeled TME or P815 tumor cells in a 4-h chromium release assay. The data indicate the mean percentage of cytotoxicity of triplicate cultures ± S.E. C, the effect of anti-CD44v7 mAbs on IL-2-induced VLS in vitro was determined by injecting mice for 4 days with IL-2, as described under “Materials and Methods,” and treating the mice with anti-CD44v7 mAbs (100 μg/mouse intraperitoneally) or isotype control mAbs (100 μg/mouse intraperitoneally) once a day for 4 days. Vascular leak was determined as described above. Asterisk indicates statistically significant difference when compared with the controls, p < 0.05.

Fig. 11. The role of CD44-HA interactions in CD44 WT and CD44v7 KO mice. A, to determine the ability of IL-2-stimulated splenocytes to bind to HA-coated plates, the splenocytes were labeled for 4 h with [3H]thymidine (5 Ci/ml). The labeled splenocytes (107 well) were added to each well of HA-coated plates and incubated for 1 h at 37°C. Non-adherent cells were removed by gently pipetting with PBS. The percentage of cells adhering to the plate was determined using the formula described under “Materials and Methods.” B, the effect of pretreatment of either LAK cells or EC with hyaluronidase on the LAK-mediated killing of EC cells was determined. Briefly, IL-2-stimulated splenocytes from CD44 WT mice and EC were untreated (control) or pretreated for 1 h at 37°C with hyaluronidase (1000 TRU/ml). After treatment, the cells were washed and EC lysis was determined using the 4-h 51Cr release assay. The data represent an effector to target ratio of 25 and indicate the mean percentage of cytotoxicity of triplicate cultures ± S.E.

isotype control mAb-treated group. Together, these results suggested that anti-CD44v7 mAbs effectively blocked LAK cell adherence to and lysis of EC and, furthermore, markedly reduced IL-2-induced VLS in vivo.

Role of CD44-HA Interactions in CD44 WT and CD44v7 KO Mice—HA is one of the major ligands for CD44. Previous reports demonstrated that activation of lymphocytes leads to increased HA binding (40, 41). It was possible that deletion of v6 and v7 exon products resulted in altered binding to HA. Therefore, we examined whether splenocytes from CD44 WT, CD44 KO, or CD44v7 KO mice exhibited altered ability to bind to HA. Following stimulation with IL-2 in vitro, splenocytes from CD44 WT and CD44v7 KO mice showed significant and comparable binding to HA-coated plates (Fig. 11A). In contrast, splenocytes from CD44 KO mice did not show any detectable binding to HA. Unactivated splenocytes, regardless of the expression of CD44, were not able to bind HA-coated plates (data not shown). In addition, we examined the effect of pretreatment of LAK cells and/or EC cells with hyaluronidase on the LAK-mediated killing of EC (Fig. 11B). The results showed that pretreatment of either LAK cells or EC with hyaluronidase had no significant effect on the ability of IL-2-stimulated cytotoxic cells to kill EC targets. Together, these results suggested that CD44v7 was not critical for the binding of IL-2-activated splenocytes to HA.

Lysis of Endothelial Cells by LAK Cells Is Suppressed by Addition of Soluble or Enzymatic Cleavage of CD44v7 Ligands—In this study we demonstrated that the ability of splenocytes from CD44v7 KO mice to bind HA was similar to that seen using cells from CD44 WT mice (Fig. 11A), thereby suggesting that the absence of CD44v7 did not alter HA binding. The expression of CD44v6-v7 has been shown to facilitate the binding to other glycosaminoglycans including chondroitin sulfate, heparin, and heparin sulfate (42). Therefore, we examined the effect of soluble chondroitin sulfate and heparin on IL-2-stimulated LAK-mediated lysis of EC and P815 tumor cells. The results showed that addition of soluble chondroitin sulfate A, B, and C and heparin caused significant inhibition in the lysis of EC (Fig. 12A) without causing any decrease in the lysis of P815 tumor cells (Fig. 12B). These data were confirmed by the fact that addition of enzymes specific for chondroitin sulfate and heparin, significantly reduced LAK cell-mediated
The Role of CD44v7 in LAK-mediated Endothelial Cell Damage

Saminoglycan enzymes. The LAK activity was determined using the 4-h age of CD44v7 specific glycosaminoglycans, LAK cells were cultured with CD44 isoforms including chondroitin sulfate, heparin, and heparin sulfates containing v6 and v7 led to increased binding to other glycosaminoglycans including chondroitin sulfate, heparin, and heparin sulfate (42). EC express such glycosaminoglycans (46), thereby suggesting the possibility that the increased expression of CD44v6-v7 on IL-2-activated lymphocytes may lead to increased binding to EC. The consequence of such increased binding could be the induction of cytotoxicity of EC resulting in vascular leak as shown in the current study. In fact, increased CD44-mediated binding of mononuclear leukocytes to target cells has been implicated in other diseases such as inflammatory bowel disease (47).

Previous studies have demonstrated that EC also express CD44 (43, 48). Thus, we cannot entirely exclude the possibility that the expression of CD44v7 on EC plays some role in IL-2-induced VLS. Nevertheless, using adoptive transfer experiments, we noted that lymphocytes transferred from CD44 WT into CD44v7 KO mice caused higher levels of IL-2-induced VLS when compared with transfer of CD44v7 KO lymphocytes into CD44v7 KO mice. Moreover, results from cross-mixing experiments demonstrated that expression of CD44v7 on LAK cells is important for killing either CD44 WT EC or CD44v7 KO EC. Together, these data suggested that expression of CD44v7 on EC plays some role in IL-2-induced VLS or ConA-induced hepatitis, the infiltration of mononuclear cells in the lungs or liver is not significantly altered in CD44v7 KO mice, which lack the entire CD44 gene (10, 44). Moreover, the binding of CD44 to HA and other ligands is tightly regulated and depends on the status of the CD44 molecule. In fact, most CD44 molecules are unable to bind HA but must be induced to bind to HA. Some factors that may be involved in inducing CD44 binding to HA include increased expression, receptor clustering, glycosylation, and sulfation (45). In addition, evidence suggests that the expression of CD44 isoforms was not necessary for binding of lymphocytes to HA on EC (43). Interestingly, it has been shown that the expression of CD44 isoforms containing v6 and v7 led to increased binding to other glycosaminoglycans including chondroitin sulfate, heparin, and heparin sulfate (42). EC express such glycosaminoglycans (46), thereby suggesting the possibility that the increased expression of CD44v6-v7 on IL-2-activated lymphocytes may lead to increased binding to EC. The consequence of such increased binding could be the induction of cytotoxicity of EC resulting in vascular leak as shown in the current study. In fact, increased CD44-mediated binding of mononuclear leukocytes to target cells has been implicated in other diseases such as inflammatory bowel disease (47).

Fig. 12. Lysis of endothelial cells by LAK cells is suppressed by addition of soluble or enzymatic cleavage of CD44v7 ligands. To determine the effect of soluble CD44v7 ligand, LAK cells were directed against endothelial cell (A) or P815 (B) in the presence of 0.5 mg/ml various glycosaminoglycans. To determine the effect of enzymatic cleavage of CD44v7 specific glycosaminoglycans, LAK cells were cultured with endothelial cells (C) or P815 (D) in the presence of various glycosaminoglycans enzymes. The LAK activity was determined using the 4-h 31Cr release assay. The data indicate the mean percentage of cytotoxicity of triplicate cultures ± S.E. Asterisk indicates a statistically significant decrease when compared with the controls, p < 0.05.

EC damage is widely reported in a number of pathological diseases including infections, autoimmunity, transplantation, graft-versus-host disease, and following immunotherapy with cytokines and immunotoxins. Previous work from our laboratory implicated CD44 expressed by cytolytic lymphocytes in IL-2-induced EC injury leading to VLS (10). However, the nature of specific isoforms of CD44 involved was unclear. Therefore, the current study was designed to determine which CD44 isoforms were involved in VLS. We demonstrated that, following IL-2 administration in vivo, the expression of CD44v7 and CD44v6-v7 was up-regulated. In addition, we demonstrated that IL-2-induced VLS was markedly abrogated in mice lacking CD44v6-v7 and CD44v7. This abrogation was not the result of decreased activation or expansion of effector cell population but was the result of reduced lytic capabilities of lymphocytes lacking the CD44v6-v7 or CD44v7 isoforms because of reduced adhesion to EC. Furthermore, the LAK cell binding to and lysis of EC in vitro and IL-2-induced VLS in vivo was blocked by anti-CD44v7 mAbs.

CD44 has been implicated in a number of immunological processes including lymphopoiesis, lymphocyte activation, homing, and leukocyte rolling and extravasation into sites of inflammation (19). Studies have shown that interactions between CD44 and HA are important in the initial attachment and rolling of lymphocytes along the endothelium (43). However, evidence from this study suggests that CD44v7 may not be critical for the interaction with HA or for lymphocyte extravasation into the lungs. IL-2-activated splenocytes from CD44 WT or CD44v7 KO mice showed similar levels of binding to HA; furthermore, pretreatment of LAK cells or EC with hyaluronidase did not affect the ability of the LAK cells to kill EC. Finally, we noted that infiltration of lymphocytes into the lungs following IL-2 treatment was not significantly altered in CD44v6-v7 KO or CD44v7 KO mice. These data are consistent with our earlier findings that, in IL-2-induced VLS or ConA-induced hepatitis, the infiltration of mononuclear cells in the lungs or liver is not significantly altered in CD44 KO mice, which lack the entire CD44 gene (10, 44). Moreover, the binding of CD44 to HA and other ligands is tightly regulated and depends on the status of the CD44 molecule. In fact, most CD44 molecules are unable to bind HA but must be induced to bind to HA. Some factors that may be involved in inducing CD44 binding to HA include increased expression, receptor clustering, glycosylation, and sulfation (45). In addition, evidence suggests that the expression of CD44 isoforms was not necessary for binding of lymphocytes to HA on EC (43). Interestingly, it has been shown that the expression of CD44 isoforms containing v6 and v7 led to increased binding to other glycosaminoglycans including chondroitin sulfate, heparin, and heparin sulfate (42). EC express such glycosaminoglycans (46), thereby suggesting the possibility that the increased expression of CD44v6-v7 on IL-2-activated lymphocytes may lead to increased binding to EC. The consequence of such increased binding could be the induction of cytotoxicity of EC resulting in vascular leak as shown in the current study. In fact, increased CD44-mediated binding of mononuclear leukocytes to target cells has been implicated in other diseases such as inflammatory bowel disease (47).

Previous studies have demonstrated that EC also express CD44 (43, 48). Thus, we cannot entirely exclude the possibility that the expression of CD44v7 on EC plays some role in IL-2-induced VLS. Nevertheless, using adoptive transfer experiments, we noted that lymphocytes transferred from CD44 WT into CD44v7 KO mice caused higher levels of IL-2-induced VLS when compared with transfer of CD44v7 KO lymphocytes into CD44v7 KO mice. Moreover, results from cross-mixing experiments demonstrated that expression of CD44v7 on LAK cells is important for killing either CD44 WT EC or CD44v7 KO EC. Together, these data suggested that expression of CD44v7 on IL-2-stimulated LAK cells, rather than EC, plays an important role in the induction of VLS.

We demonstrated that treatment with IL-2 in vivo led to the expansion of CD8 T cells, NK cells, and NK-T cells in both CD44 WT and CD44 KO mice. Additionally, we showed that splenocytes activated in vitro or in vivo with IL-2 efficiently killed EC targets while leaving fibroblast targets unharmed. The fact that both the fibroblast and EC used in this study had the same MHC would suggest that the killing of the endothelial cells was MHC-unrestricted and specific for EC. These data also suggested that the induction of vascular leak is mediated by IL-2-activated LAK cells. This is further supported by earlier studies showing that IL-2-activated LAK cells can adhere to and kill EC targets (49). In addition, the toxic side effects induced by IL-2 were significantly reduced following NK cell depletion (50). In addition, previous studies from our laboratory showed that mice deficient in FasL or perforin had markedly decreased VLS (9).

In a study by Baluna et al. (51), it was reported that IL-2 coupled to mouse IgG could bind directly to and cause damage to EC. However, in the current study we did not see any direct toxicity to endothelial cell cultures following exposure to IL-2.
in vitro (data not shown). This apparent discrepancy could be the result of differences in experimental set-up. In the study by Baluna et al., the presence of mouse IgG was necessary for the induction of IL-2-mediated EC damage. In our experiments examining the direct toxic effects of IL-2 on EC, mouse IgG was not added. In addition, studies suggest that exposure of EC to IL-2 does not affect the expression of a number of molecules involved in the adhesion between lymphocytes and EC. For example, exposure of EC to IL-2 had no direct effect on the expression of hyaluronan, P-selectin, E-selectin, ICAM-1, ICAM-2, VCAM-1, and PECAM-1 (52, 53). The effect of IL-2 on the EC expression of heparin, heparin sulfate, chondroitin sulfate, and other CD44 ligands remains to be fully elucidated. Together, these data suggest that IL-2 acts primarily on the lymphocyte population leading to increased adherence to and damage of EC.

Previously, we demonstrated that Fas ligand and perforin play an important role in the induction of vascular leak (9). This work suggested that blocking perforin or Fas ligand may reduce IL-2-induced EC damage and vascular leak, thereby facilitating tumor immunotherapy. However, because perforin and Fas ligand play an important role in lymphocyte killing of tumors, blocking perforin and/or Fas ligand may also decrease the efficacy of IL-2 therapy in the treatment of cancers. This is supported by our findings of reduced killing of YAC-1 tumor targets in glt and perforin KO mice (9). In contrast, in the current study, we noted that blocking CD44v7 decreased the killing of EC but not P815 tumor cells. Therefore, targeting CD44 isoforms may offer an alternate and effective approach to reducing VLS without affecting tumor killing.

We and others have shown that ligation of CD44 can signal the induction of cytolytic activity in CTL and NK cells (20, 24). Interestingly, these pathways can be distinguished from natural cytotoxic activities of LAK cells (24) demonstrated that PI 3-kinase and tyrosine kinase played a part, by interactions with various glycosaminoglycans such as chondroitin sulfate, and heparin. Previously, Sconocchia et al. (1985) demonstrated that PI 3-kinase and tyrosine kinase activated tumor targets in glt and perforin KO mice (9). In contrast, in the current study, we noted that blocking CD44v7 decreased the killing of EC but not P815 tumor cells. Therefore, targeting CD44 isoforms may offer an alternate and effective approach to reducing VLS without affecting tumor killing.

In the current study we observed that activation of splenocytes with IL-2 up-regulates CD44 expression. Interestingly, when we separated CD44hi and CD44lo cells from the activated population, only CD44hi but not CD44lo cells had the potential to kill EC. These findings are highly significant because it may be possible to isolate such cells from tumor-bearing or immunized host and be used for immunotherapy. Alternatively, it is possible to target such cells with antibodies or fusion proteins to cause their depletion in vivo, as a treatment modality to prevent transplant rejection, graft-versus-host diseases, allergies, etc.

In conclusion, this study demonstrates for the first time that CD44v7 plays a critical role in EC injury and vascular leak caused by IL-2. CD44v7 deficiency does not affect the activation, Fas ligand, and perforin expression or the migration of LAK cells. In addition, we observed that LAK cells from CD44v7 KO mice are able to kill P815 tumor targets to the same extent as LAK cells from CD44 WT mice. Therefore, by blocking the interaction between CD44v7 and the appropriate ligands on the EC, such as by using anti-CD44v7 antibodies or siRNAs directed against CD44v7, it may be possible to reduce IL-2-induced vascular damage. This may affect the antitumor efficacy of IL-2 therapy. Patients with metastatic disease have poor prognosis and a 5-year survival rate of less than 10% (54). High dose IL-2 therapy has a response rate of up to 30% in patients with metastatic melanoma, renal cell carcinoma, and non-Hodgkin’s lymphoma (55, 56). Thus, to date, the best systemic therapy for treating metastatic disease is high dose IL-2. Our studies shed new light not only in understanding the basic mechanisms involved in the interactions between LAK cells and EC but also provide useful information in improving immunotherapy of cancer using IL-2.
35. Mustafa, A., McKallip, R. J., Fisher, M., Duncan, R., Nagarkatti, P. S., and Nagarkatti, M. (2002) J. Immunother. 25, 476–488
36. Udaka, K. (1970) Proc. Soc. Exp. Biol. Med. 133, 1384
37. Li, L., Elliott, J. F., and Mosmann, T. R. (1994) J. Immunol. 153, 3967–3978
38. Marelli-Berg, F. M., Peek, E., Lidington, E. A., Stauss, H. J., and Lechler, R. I. (2000) J. Immunol. Methods 244, 205–215
39. McKallip, R. J., Do, Y., Fisher, M. T., Robertson, J. L., Nagarkatti, P. S., and Nagarkatti, M. (2002) Int. Immunol. 14, 1015–1026
40. Liu, D., Zhang, D., Mori, H., and Sy, M. S. (1996) Cell. Immunol. 174, 73–83
41. Lesley, J., and Hyman, R. (1992) Eur. J. Immunol. 22, 2719–2723
42. Sleeman, J. P., Kondo, K., Moll, J., Ponta, H., and Herrlich, P. (1997) J. Biol. Chem. 272, 31837–31844
43. Nandi, A., Estess, P., and Siegelman, M. H. (2000) J. Biol. Chem. 275, 14939–14948
44. Chen, D., McKallip, R. J., Zeytun, A., Do, Y., Lombard, C., Robertson, J. L., Mak, T. W., Nagarkatti, P. S., and Nagarkatti, M. (2001) J. Immunol. 166, 5889–5897
45. Pure, E., and Cuff, C. A. (2001) Trends Mol. Med. 7, 213–221
46. Robinson, M. J., Tessier, P., Poulsom, R., and Hogg, N. (2002) J. Biol. Chem. 277, 3658–3665
47. de La Motte, C. A., Hascall, V. C., Calabro, A., Yen-Lieberman, B., and Strong, S. A. (1999) J. Biol. Chem. 274, 30747–30755
48. Savani, R. C., Cao, G., Pooter, P. M., Zaman, A., Zhou, Z., and DeLisser, H. M. (2001) J. Biol. Chem. 276, 36770–36778
49. Damle, N. K., Doyle, L. V., Bender, J. R., and Bradley, E. C. (1987) J. Immunol. 138, 1779–1785
50. Peace, D. J., and Cheever, M. A. (1989) J. Exp. Med. 169, 161–173
51. Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V., and Vitetta, E. S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3957–3962
52. Estess, P., Nandi, A., Mohamadzadeh, M., and Siegelman, M. H. (1999) J. Exp. Med. 190, 9–19
53. Beekhuizen, H., and van de Gevel, J. S. (1998) Transplant Proc. 30, 4251–4256
54. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Esnler, J. H., and White, D. E. (1994) JAMA 271, 907–913
55. Malaguarnera, M., Ferlito, L., Gulizia, G., Di Fazio, I., and Pistone, G. (2001) Eur. J. Clin. Pharmacol. 57, 267–273
56. Rosenberg, S. A. (2001) Nature 411, 380–384